M&A / Deals Daiichi Sankyo and Waiv partner for ADC biomarkers Pharmaceutical TechnologyDaiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme.OncologyRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) Pharmaceutical Technology Daiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme. Oncology Read full story Post navigation Previous: Halozyme and Oruka sign agreement for Hypercon technologyNext: Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026